Format

Send to

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5191-4. doi: 10.1016/j.bmcl.2010.07.005. Epub 2010 Jul 8.

Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery.

Author information

1
Michigan Nanotechnology Institute for Medicine and Biological Sciences, Department of Internal Medicine, Division of Allergy, University of Michigan, Ann Arbor, MI 48109, USA.

Abstract

This communication describes the synthesis and in vitro biological evaluation of novel generation 5 PAMAM dendrimers conjugated with riboflavin as a targeting ligand. Cell-based experiments demonstrated that a dendrimer conjugated with riboflavin is able to undergo cellular binding and uptake in KB cells, and when the dendrimer is also conjugated with methotrexate, the riboflavin dendrimer conjugate can potently inhibit cell growth.

PMID:
20659800
PMCID:
PMC2922453
DOI:
10.1016/j.bmcl.2010.07.005
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center